New incident report
Incident Report Number: 2019-3164
Registrant Reference Number: USA-BAYERBAH-2019-US0025811 (Report 567453)
Registrant Name (Full Legal Name no abbreviations): Bayer inc
Address: 2920 Matheson Blvd
City: Mississaugua
Prov / State: ON
Country: Canada
Postal Code: L4W 5R6
Domestic Animal
Country: UNITED STATES
Prov / State: GEORGIA
PMRA Registration No. PMRA Submission No. EPA Registration No. 11556-152
Product Name: Advantage II Large Cat (Imidacloprid-Pyriproxyfen)
Other (specify)
spot onYes
Units: mL
Site: Animal / Usage sur un animal domestique
Animal's Owner
Cat / Chat
Domestic Shorthair
1
Male
2
4.536
kg
Skin
>8 hrs <= 24 hrs / >8 h <= 24 h
<=30 min / <=30 min
System
Persisted until death
Yes
Yes
Unknown
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
Approximately 10 minutes post application, the cat developed hypersalivation. Approximately 12 hours post product application, the cat developed vocalization, intermittent vomiting, diarrhea and inappropriate defecation. The owner bathed the cat with liquid dish soap. On 28-May-2019, the cat was examined by a veterinarian and exhibited weight loss to 9 pounds, shallow breathing, relunctance to move, was mentally obtunded and was vocalizing. The cat was hypothermic with a temperature of 92 degrees Fahrenheit, and reflexes were absent. The cat had a an increased respiratory rate 50 breaths per minute, pale mucous membranes and the pupils were miotic but responsive. Feline leukemia virus and feline immunodeficiency virus tests were performed and were negative. Additional unspecified bloodwork was performed with unknown results. The cat was treated with lactated ringers solution at a rate of 20 ml per hour intravenously, buprenorphine 0.01 ml intramuscularly, cefovecin sodium 0.25 ml subcutaneously, and lactated ringers solution 150 ml subcutaneously. The respiratory rate increased to 56 breaths per minute, the fluid rate was decreased to 15 ml per hour and the cat was administered oxygen therapy. The cat exhibited seizures and agonal breathing (abnormal breathing). The cat was treated with diazepam 0.15 ml intravenously and epinephrine 0.3 ml via the intravenous route by the veterinarian. Cardiopulmonary resuscitation was performed but was unsuccessful and the cat died. No necropsy was performed. Follow up received on 31st May 2019: Approximately 12 hours post product application, the cat developed vocalization, intermittent vomiting, diarrhea and inappropriate defecation. Tremors occurred an unspecified time post application. The owner bathed the cat with liquid dish soap. On 28-May-2019, the cat was examined by a veterinarian and exhibited weight loss to 9 pounds, shallow breathing, relunctance to move, application site erythema, was mentally obtunded and was vocalizing.
Death
O - Unclassifiable/unassessable Reported digestive disorders are unspecific and may have many potential causes. Signs are not expected after topical product use and oral product uptake was not witnessed. Vocalisation and reluctant to move are unspecific and may have various other causes. Animal had concomitant condition of lethargy. Reported tremor is not expected with appropriate topical product use. No oral product exposure witnessed. Further reported weight loss, pale mucous membrane, hypothermia, tachypnea, shallow breathing are not expected either. Weight loss is rather suggestive of a more chronic underlying pathology. In individual cases, dermal reaction such as erythema at the application site is possible in animals that are particular sensitive. Constricted pupils, depressed reflexes and mental impairment are not expected and may be associated with seizures. Serious nervous system disorder such as seizure is not anticipated with topical administration of Advantage II. From a toxicological point of view, neither imidacloprid nor pyriproxyfen does have the potential to provoke seizures in vertebrates. In case of oral ingestion of a considerable amount of product or after administration of an overdose shortly after product application, neurological symptoms such as tremor, ataxia, depression, miosis or mydriasis may occur. But seizures are not expected. Abnormal breathing is likely associated with seizure. Death is inconsistent with pharmaco-toxicological product profile and experience. Product has wide margin of safety. Oral LD50 in rat is 642 mg/kg BW. 24-fold overdosage tolerated by cats without showing any side effect. Though time to onset is consistent, considering overall aspects, a product relation for the case is unassessable.